{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ARCT",
  "name": "Arcturus Therapeutics Holdings Inc.",
  "url": "https://orbyd.app/dossiers/ARCT/",
  "json_url": "https://orbyd.app/dossiers/ARCT.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "CSL exit hands back global KOSTAIVE plus flu/RSV/EBV rights, $12M cash and ~$16M of released liabilities, against $191.5M cash and runway guided through end-2028 — a platform-repossession re-rating that has run 91.3% in three months into an RSI(14) of 92.8. The undated ARCT-810 Phase 2 OTC readout, guided by 2026-09-30, is the near binary.",
  "invalidation_trigger": "A weekly close below $11 unwinds the August expansion leg; secondary, the ARCT-810 Phase 2 OTC window closing on 2026-09-30 with no data and no regulatory plan disclosed.",
  "catalyst_date": "2026-09-30",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "rare-disease-gene-therapy",
    "ai-enterprise-software",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Revenue is collaboration- and grant-driven and lumpy; quarterly revenue prints are not a demand signal for this company.",
    "Cash runway guidance through year-end 2028 was given on 2026-08-06, before the guided Q4 2026 decision on whether to run an ARCT-032 Phase 3.",
    "KOSTAIVE in Japan remains subject to existing Meiji Seika Pharma arrangements for the 2026-2027 season despite the global rights return.",
    "Clinical-stage issuer with no product revenue base: equity issuance capacity is a standing feature; check EDGAR for 424B5 filings before reading any price move."
  ],
  "body_markdown": "\n> **Life-cycle: ACCELERATING.** Dated by the vaccine-rights coverage of 2026-08-19, the sector-wide mRNA headline day of 2026-08-20, and an RSI(14) of 92.8 at the 2026-08-21 close of $13.45. The qualifier matters: this is acceleration inside a recovery, with the shares still 41.9% under the 52-week high of $23.16.\n\n## ARCT — Arcturus Therapeutics Holdings Inc.\n\n## Current Thesis\nThe leg being bought is platform re-possession. The CSL Seqirus collaboration was terminated by settlement: Arcturus regained global rights to KOSTAIVE and the wider sa-mRNA infectious-disease portfolio (seasonal and pandemic influenza, RSV, EBV), took a one-time $12M cash payment, was released from roughly $16M of R&D-credit liabilities, and resolved the arbitration over a European approval milestone — all disclosed with Q2 2026 results on 2026-08-06 and picked up by trade coverage on 2026-08-19. Stacked on that is a rare-disease readout the company has guided to but not dated: ARCT-810 Phase 2 data and regulatory plan in ornithine transcarbamylase deficiency, \"later this quarter\", i.e. by 2026-09-30. The market has already paid for a good outcome — up 91.3% over three months into a 14-day RSI of 92.8 on 2026-08-21.\n\n## Bull Case\n- **Balance sheet is not the constraint.** $191.5M in cash and equivalents at 2026-06-30, with runway guided \"over two and a half years through year end 2028\" (Q2 2026 release, 2026-08-06). A clinical-stage name with two Phase 2 programs and no immediate funding cliff is unusual in this cohort.\n- **The CSL unwind was cash-positive, not cash-negative.** $12M received, ~$16M of liabilities released, arbitration closed, and an EU/Japan-approved sa-mRNA COVID vaccine plus flu/RSV/EBV programs returned to full ownership (2026-08-06).\n- **Q2 loss came in narrower than the street.** EPS of -$0.84 against a -$1.00 consensus; net loss $23.8M on R&D of $17.5M and G&A of $11.0M (2026-08-06). Revenue of $2.959M missed the $3.199M consensus, which is the smaller line in a company of this shape.\n- **ARCT-032 tolerability so far.** More than 50 participants dosed at up to 15 mg for 28 days without steroid pre-treatment; cohort 4 is running 10 mg daily over a 12-week treatment period with pulmonary-function and safety endpoints (Q2 2026 disclosure). Phase 2 sites are enrolling in the U.S., Israel and Turkey.\n- **A named manufacturing partner ahead of Phase 3.** Thermo Fisher Scientific collaboration for ARCT-032 Phase 3 manufacturing and clinical supply, announced with Q2 results 2026-08-06 — a capex-light route into a registrational trial.\n- **Sell-side has not chased it down.** Canaccord Genuity kept a Buy and moved its target to $20 from $21 in coverage dated 2026-08-19, after the CSL exit.\n\n## Bear Case\n- **Regaining rights is a bill, not a payment.** Flu, pandemic flu, RSV and EBV programs now sit inside a company generating $2.959M of quarterly revenue against $28.5M of combined Q2 R&D and G&A. Until a new vaccine partner is named, the returned portfolio consumes rather than funds.\n- **Runway guidance predates the biggest spending decision.** The through-year-end-2028 statement was made 2026-08-06; the ARCT-032 Phase 3 go/no-go is guided for Q4 2026. Whether that runway survives a self-funded Phase 3 is unresolved — an inference, not a disclosure.\n- **The OTC readout is a window, not a date.** \"Later this quarter\" gives management until 2026-09-30. Data that slips past that boundary, or arrives without a stated registrational path, is a negative even if the numbers look fine.\n- **The market has been here before.** $23.16 was printed inside the last 52 weeks and did not hold; price is 41.9% below it. The recovery is climbing back through prior distribution.\n- **CF competitive frame.** ARCT-032 addresses cystic fibrosis patients not served by CFTR modulators, which is a narrower commercial segment than the modulator franchise itself — the pricing of any Phase 3 decision has to carry that.\n\n## Setup & Price Structure\nThe last completed daily close was $13.45 on 2026-08-21. Three-month price change of +91.3%. RSI(14) of 92.8 — a reading above 90 on a 14-day lookback is a rare, mechanically stretched state, and it arrived while the shares were still 41.9% beneath the $23.16 52-week high. The structure is a violent retracement rally into overhead supply.\n\nCrowding observables, stated as observables: retail-facing coverage clustered inside three sessions — Benzinga healthcare-movers round-ups on 2026-08-19 (pre-market) and 2026-08-21 (intraday), plus StocksToTrade and Timothy Sykes pieces both dated 2026-08-19 framing the move as \"vaccine rights return and cash pile grows\". The 2026-08-20 mRNA-sector headline day (Musk comments following Moderna/Merck cancer-vaccine news; MRNA itself down over 11% pre-market that session) put group-level attention on the complex. No Form 4 insider sales and no prospectus supplement appear in the filing record reviewed as of 2026-08-22; that is an absence of evidence, and for a small-cap biotech 91.3% higher over a quarter it is the single line worth re-checking on EDGAR before anything else.\n\nOnly the adjusted daily-close series is in hand here, so the $11 threshold used below is a chosen retracement marker for the August expansion, not a verified intraday shelf.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-30 (est., company-guided window)** — ARCT-810 Phase 2 OTC deficiency data plus regulatory plan. Enrollment and dosing were completed in Q2; the guidance is \"later this quarter\", so any session between now and quarter-end is live. This is the near-term binary.\n- **Q4 2026 (guided)** — ARCT-032 cystic fibrosis Phase 3 go/no-go decision. Outside the 30-day window, but it is the event the current multiple is reaching for.\n\n## Elapsed catalysts\n\n- **No company-confirmed investor-conference appearance was found for September 2026 as of 2026-08-22.** September healthcare conference season is an obvious venue for the OTC dataset, but participation is unconfirmed and should not be assumed. *(passed 1d ago)*\n\n## What Would Change Our Mind\nThe cleanest break is calendar, not chart: the ARCT-810 window closes 2026-09-30, and a quarter-end that passes with no OTC data and no regulatory plan removes the reason the name re-rated in August, regardless of where it trades. Second, a financing. A prospectus supplement or offering 8-K into this strength would recast the \"$191.5M, funded to 2028\" line that anchors the bull case and would say management does not think the runway covers a CF Phase 3.\n\nOn price, a weekly close below $11 unwinds the August expansion leg and reframes the RSI-92.8 thrust as a failed move rather than the first leg of a recovery. On the other side, the read strengthens if ARCT-810 data lands inside the window with a named registrational path, or if a partner is announced for the returned influenza/RSV portfolio — either would convert the rights-return story from optionality into funded programs.\n\n## Correlation Notes\n- **mRNA complex beta.** MRNA, BNTX and CVAC set the group tone; 2026-08-20 showed the linkage is not clean — Moderna fell more than 11% pre-market on a day the broader mRNA narrative was being amplified. Sector headlines move ARCT, but sign is not guaranteed.\n- **Vertex (VRTX)** is the read-across for the CF program: any modulator-label expansion narrows the population ARCT-032 is aimed at.\n- **Small-cap biotech risk appetite (XBI)** dominates on non-news days; a name up 91.3% in three months with no revenue base trades as a high-beta expression of that appetite.\n- **Meiji Seika Pharma** remains the Japan channel for KOSTAIVE for the 2026-2027 season under existing arrangements, so the returned rights are not immediately unencumbered in that market.\n- **US vaccine policy** is a live input for the value of a returned COVID/flu vaccine portfolio; policy actions land on the whole complex at once, not on ARCT alone.",
  "first_seen": "2026-08-20",
  "last_analyzed": "2026-08-22T07:05:20+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}